drugset
drugset / Trial / NCT05084053

A Study of TAK-771 in Japanese Participants With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) and Multifocal Motor Neuropathy (MMN)

NCT05084053 ↗

Phase 3 Completed 26 enrolled Takeda
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The main aim of the study is to check for side effects from TAK-771, and to check how well TAK-771 controls symptoms in Japanese participants with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) and multifocal motor neuropathy (MMN) The participants will be treated with TAK-771 for 45 months as a maximum. There will be many clinic visits. The number of visits will depend on the infusion cycles of study drug (every 2, 3, or 4 weeks).

Timeline

Start
2022-01-19
Primary completion
2025-10-28
Completion
2026-05-29

Drugs

EvaluationDrugModalityDoseRoute
Subject Immune Globulin Infusion Protein / enzyme biologic 10 % Subcutaneous
Subject rHuPH20 Protein / enzyme biologic 80 unknown Subcutaneous

Indications

chronic inflammatory demyelinating polyradiculoneuropathy multifocal motor neuropathy